Home › Lung Cancer › NCT07398209
GCC 2546- Motion Management
Combining 4D MRI and 4DCT for Personalized Volumetric Motion Monitoring in Lung Radiation Therapy
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Adult (≥18 years) patients (both sexes) with histologically diagnosed Stage II-IIIb NSCLC 2. Patients to be treated with definitive external beam photon radiotherapy with or without systemic therapy (e.g., chemotherapy, immunotherapy). 3. No restrictions on number radiotherapy fractions, or location/number of lesions 4. ECOG performance status ≤ 3 5. Ability to undergo MRI scans 6. Patient has signed informed consent document and agreed to study procedures Exclusion Criteria: 1. Pre-existing contraindications for MRI, such as any MRI-conditional or MRI-unsafe foreign objects within the body, non-removable ear cochlear or eye implant, aneurysm clip, cardiac pacemaker/wires, internal defibrillator, tissue expander, recent stent placement, penile prosthesis, medication patch, artificial limb, pregnancy, and claustrophobia 2. Women who are pregnant or trying to get pregnant (self-reported) 3. Pain in supine position or inability to raise arm above head in supine position
About the study
The purpose of this study is to assess a real time motion tracking of lung tumors and important organs next to the tumor while breathing during a participant's radiation treatment. This will be assessed through a four-dimensional magnetic resonance imaging (MRI) scan before starting your radiation treatment and x-ray fluoroscopy images that are taken during radiation
What is being tested
- MRI (other)
Sponsor: University of Maryland, Baltimore · Participants: 44 · Started: Apr 14, 2026
Contact the study team
- Amit Sawant, PhD · Phone: 410-328-6080
- Caitlin Eggleston, MPH · Phone: 410-369-5351
Official record on ClinicalTrials.gov — NCT07398209
Locations in the U.S.
| Maryland | University of Maryland Greenebaum Cancer Center, Baltimore |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.